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ritical Determinants
f Limb Ischemia*
ohn P. Cooke, MD, PHD, FACC
tanford, California
eripheral arterial disease (PAD) involving the lower ex-
remities affects 8 to 12 million Americans (1). Typically,
AD is secondary to atherosclerotic occlusive disease of the
ortoiliac, femoral, popliteal, and/or the infrapopliteal ar-
eries. The clinical manifestations depend in part on the
evel of disease and its severity. The classic symptom of
ntermittent claudication (pain with walking, relieved by
est) typically involves the calf, but the thigh and/or but-
ocks can be affected with more proximal arterial disease.
lassic symptoms are only manifested by 10% to 30% of
atients (2,3). More often, the patients are asymptomatic, or
heir symptoms are disguised by (or attributed to) associated
iabetic neuropathy or musculoskeletal disorders, each of
hich are common in the demographic affected by PAD.
See page 387
A more severe form of PAD is characterized by pain at
est (typically in the foot, occurring often at night, and
elieved by dependency). These individuals have a limb in
eopardy, and the most minor trauma (from a poorly fitting
hoe, or a carelessly clipped toenail) can result in a nonheal-
ng wound, infection, and amputation. This form of PAD is
nown as critical limb ischemia, and affects about 10% of
AD patients. Critical limb ischemia (CLI) is a mortal
llness: at 1 year after presentation, 30% have suffered an
mputation and 25% of patients are dead (4).
hy Are There Differences
n the Clinical Presentation of PAD?
lthough hemodynamically significant obstructions of the
onduit arteries play an acknowledged role in the manifes-
ations of PAD, there is considerable heterogeneity in the
egree of symptoms. Furthermore, there is only a modest
orrelation of hemodynamic assessments, such as the ankle-
rachial index (ABI) (the pressure at the ankle divided by
Editorials published in the Journal of the American College of Cardiology reflect the
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edicine, Stanford, California.he pressure at the arm), with functional capacity as assessed
y treadmill testing (5). This heterogeneity may be in part
ue to individual differences in the response of the skeletal
uscle to ischemia. For example, the expression and activity
f key mitochondrial enzymes are altered in skeletal muscle
rom PAD patients, and mitochondrial electron transport is
mpaired (6). Metabolic byproducts of fatty acid oxidation,
he acylcarnitines, accumulate in both the plasma and the
keletal muscle of patients with PAD, and are strongly
orrelated with impairment in exercise capacity (6).
The vascular response to conduit vessel occlusion also
eems to be subject to individual variation. Measures of skin
icrocirculation have been used prospectively to predict
mputation in CLI patients with unreconstructable vascular
isease (7). In patients with reduced skin capillary density
20/mm2), low transcutaneous oxygen (TcPO2 10 mm
g), and absent reactive hyperemia, limb survival at 1 year
as only 15%, compared with 88% in CLI patients with
reater values for the skin microcirculation.
Furthermore, it is widely recognized that collateral vessel
ormation is heterogeneous in patients with the same degree
f conduit vessel obstruction. In 1 patient with a superficial
emoral artery occlusion, robust collateral formation (arte-
iogenesis) via the deep femoral artery and geniculate
ollaterals will revascularize the infrapopliteal vessels. The
atient may have minimal or no symptoms. Another patient
ill be significantly limited by the same occlusive disease, in
setting of sparse collateral formation.
egulation of Angiogenesis
hat is responsible for the heterogeneity of vascular regen-
ration in PAD patients? An important clue has been
rovided by the work of Findley et al. (8) in this issue of the
ournal. These investigators studied healthy control subjects
nd patients with peripheral arterial disease (PAD) mani-
ested as intermittent claudication (IC) or as CLI. In these
atients they measured plasma levels of proteins from 2
amilies of angiogenic growth factors, the vascular endothe-
ial growth factors (VEGFs) and the angiopoietins (Ang).
The vascular endothelial growth factors (VEGF-A, -B,
C, and -D, and placental growth factor) and the angiopoi-
tins (Ang1 and -2) are major mediators of angiogenesis and
ymphangiogenesis (9). The receptors for the VEGFs in-
lude VEGFR-1, -2, and -3, whereas the angiopoietin
eceptors include Tie1 and -2. The diversity of angiogenic
actors and their receptors permits fine-tuning of the angio-
enic response as new capillaries form and differentiate, and
llows for specificity.
The prototype member of the VEGF family is VEGF-A.
he loss of a single allele of VEGF-A is embryonically
ethal because of failure of hematopoiesis and vasculogen-
sis. VEGF-A has 4 isoforms, including the one analyzed in
he Findley study, VEGF165. The various isoforms of
EGF induce endothelial cell proliferation, migration, and
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dhesion, and survival, acting through their endothelial
eceptor Tie2. Genetic disruption of Tie2 also results in
mbryonic lethality because of vascular defects (10).
Findley et al. (8) noted higher plasma levels of the
ngiogenic cytokines Ang2 and VEGF in the PAD pa-
ients. Furthermore, plasma levels of VEGF were signifi-
antly greater in those with more severe disease, that is, in
atients with CLI. The levels of Ang2 also tended to be
igher in the CLI patients (the lack of statistical significance
as likely a type II error because of insufficient numbers of
atients in this small study). These findings are consistent
ith the notion that greater ischemia is associated with
reater activation of the angiogenic response to hypoxia.
arenthetically, much of the hypoxic response is under the
ontrol of the transcriptional factor, hypoxia-inducible fac-
or (HIF)-1. At low oxygen tension, HIF-1 is stabilized
nd can translocate to the nucleus to orchestrate the genetic
esponse to ischemia, activating genes encoding angiogenic
ytokines, metabolism, vasodilation, and cell survival (11).
ndogenous Inhibitors of Angiogenesis
f relevance to this study, it is known that the angiogenic
eceptors VEGFR-1 and Tie2 can be released by endothe-
ial cells into the circulation. These solubilized receptors can
till bind their respective growth factors. By scavenging
EGF or Ang, these soluble receptors may act as a brake on
ngiogenesis. The soluble receptors may represent a form of
egative feedback, because VEGF is known to promote the
ndothelial shedding of Tie2 (12). Notably, overexpression
f either of these soluble receptors in animal models inhibits
umor angiogenesis and tumor growth (13,14). The logical
xtension of these fundamental insights, a soluble VEGF
eceptor for inhibition of tumor angiogenesis and growth, is
howing promise in early clinical trials (15).
Could endogenous soluble receptors, scavenging angio-
enic cytokines, play an adverse role in the angiogenic
esponse to PAD? Intriguingly, Findley et al. (8) also
bserved an increase in the plasma levels of the soluble Ang
eceptor (sTie2) in the PAD patients. Furthermore, the
lasma levels of sTie2 were highest in the most symptomatic
atients. The greater elevation of sTie2 in the CLI patients
emained after controlling for differences in CV risk factors
r ABI. These findings suggest that increased levels of sTie2
orrelate with the severity of disease, independently of the
emodynamic impairment.
One might speculate that the elevation of the soluble
eceptor impairs the angiogenic response in these patients.
o confirm this hypothesis, it would be useful to study a
arger group of PAD patients, including asymptomatic to
ost symptomatic subjects. One would correlate plasma
evels of the angiogenic cytokines and their soluble receptors
o an angiographic assessment of collaterals, as well as
apillary density in needle biopsies of calf muscle. Individ-
als with greater levels of the angiogenic cytokines andower levels of the soluble receptors would be expected to
ave a greater angiogenic response.
ew Insights Into Angiogenic Modulation
he notion that individual patients may have different
esponses to the same ischemic stimulus finds support in the
oronary circulation. Recently, a genetic variant of HIF-1
as been described. Patients with coronary artery disease
ho also had this genetic variant were observed to have
ewer coronary collateral vessels (16). Undoubtedly, other
enetic factors will be found to play a role in the heteroge-
eity of vascular regeneration in response to ischemia.
ndeed, the Duke group is continuing their hunt in C57Bl/6
ice, where a segment of chromosome 7 containing 37
enes confers resistance to limb loss after femoral artery
igation (17). One or more of these genes may be involved
n the enhanced angiogenic response and superior perfusion
bserved in this strain of mice. Taken together, the trans-
ational studies of Findley et al. (8) will provide new clues to
he mechanisms underlying impaired vascular regeneration
n PAD, and may lead us to new therapeutic approaches to
romote arteriogenesis and to enhance angiogenesis.
eprint requests and correspondence: Dr. John P. Cooke, Falk
ardiovascular Research Center, Stanford University School of
edicine, 300 Pasteur Drive, Stanford, California 94305-5406.
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